Duke doctor named new chair of NCCN board of directors

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 4
Volume 19
Issue 4

Thomas A. D’Amico, MD, has been elected chair of the board of directors of the National Comprehensive Cancer Network.

Thomas A. D'Amico, MD, has been elected chair of the board of directors of the National Comprehensive Cancer Network.

Dr. D'Amico is director of clinical oncology, program director of thoracic surgery, and professor in the department of surgery at Duke Comprehensive Cancer Center at Duke University in Durham, N.C.

His areas of expertise include the molecular biology of lung cancer, esophageal cancer, and also thoracic surgery. He is a member of several NCCN committees, and serves on the NCCN guidelines panel for esophageal/gastric cancers as well as on the panel for non-small-cell lung cancer.

Dr. D'Amico was previously vice-chair of the NCCN board and succeeds Al B. Benson III, MD, as chair.

Recent Videos
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Greater cancer treatment longevity enables oncologists the ability to form more impactful relationships with their patients.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content